- Molecular NameSparfloxacin
- SynonymNA
- Weight392.406
- Drugbank_IDDB01208
- ACS_NO110871-86-8
- Show 3D model
- LogP (experiment)-0.02
- LogP (predicted, AB/LogP v2.0)-0.23
- pka8.0
- LogD (pH=7, predicted)-2.42
- Solubility (experiment)0.0899 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-3.17
- LogSw (predicted, AB/LogsW2.0)0.04
- Sw (mg/ml) (predicted, ACD/Labs)0.24
- No.of HBond Donors4
- No.of HBond Acceptors7
- No.of Rotatable Bonds3
- TPSA98.9
- StatusFDA approved
- AdministrationN/A
- PharmacologyA fluoroquinolone antibiotic used in the treatment of bacterial infections. It has a controversial safety profile.
- Absorption_value90.0
- Absorption (description)Well absorbed following oral administration with an absolute oral bioavailability of 92%. Unaffected by administration with milk or food, however concurrent administration of antacids containing magnesium hydroxide and aluminum hydroxide reduces the oral bioavailability of sparfloxacin by as much as 50%.
- Caco_2N/A
- Bioavailability92.0
- Protein binding45.0
- Volume of distribution (VD)3.9 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic glucuronidation Cytochrome P450 system not involved
- Half life20 (16~30) h
- ExcretionFecal (50%) and renal (50%)
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySingle doses of sparfloxacin were relatively non-toxic via the oral route of administration in mice, rats, and dogs. No deaths occurred within a 14-day post-treatment observation period at the highest oral doses tested, up to 5000 mg/kg in either rodent species, or up to 600 mg/kg in the dog. Clinical signs observed included inactivity in mice and dogs, diarrhea in both rodent species, and vomiting, salivation, and tremors in dogs.
- LD50 (rat)N/A
- LD50 (mouse)N/A